Welcome to our dedicated page for Qiagen news (Ticker: QGEN), a resource for investors and traders seeking the latest updates and insights on Qiagen stock.
QIAGEN N.V. develops Sample to Insight technologies for extracting, purifying, amplifying and interpreting DNA, RNA and proteins. Its recurring news covers life sciences and molecular diagnostics applications, including sample technologies, assay technologies, bioinformatics and laboratory automation used in clinical healthcare, pharmaceutical research, academia, forensics and other research settings.
Company updates frequently address product and regulatory developments across QuantiFERON tuberculosis testing, QIAstat-Dx syndromic testing panels, QIAcuity digital PCR, QIAGEN Digital Insights and automated sample-preparation systems such as QIAsymphony and QIAstat-Dx Rise. Financial news also tracks sales trends across consumables, instruments and services, profitability measures, capital-return actions, acquisitions, and changes affecting portfolio growth areas.
Summary not available.
Summary not available.
QIAGEN announced that its QIAstat-Dx syndromic testing solution will soon be available in Japan for detecting over 20 respiratory diseases from a single patient sample. This launch follows IVD approval and is expected in mid-2023, pending reimbursement decisions. With over 3,500 QIAstat-Dx instruments installed globally by the end of 2022, the system is designed for easy operation and provides actionable results in about one hour using PCR technology. The QIAstat-Dx platform allows for multiplex real-time PCR testing and unique access to Ct values and amplification curves, aiding clinical decision-making. >QIAstat-Dx connects to the QIAsphere cloud-based platform for remote monitoring, enhancing diagnostic capabilities across hospitals and labs.
QIAGEN has announced the appointment of Steve Rusckowski to its Supervisory Board. He will stand for election at the Annual General Meeting on June 22, 2023. Rusckowski is a prominent healthcare executive, previously serving as the Chairman, President, and CEO of Quest Diagnostics. He brings extensive experience from his leadership roles, including his tenure at Philips Healthcare. Lawrence Rosen, Chair of the Supervisory Board, expressed confidence that Rusckowski's expertise will contribute to QIAGEN’s future success, especially in navigating a challenging macroeconomic environment. QIAGEN is a global leader in providing solutions for molecular insights from biological samples, serving over 500,000 customers worldwide across various sectors.
QIAGEN has launched QIAseq Targeted cfDNA Ultra Panels, enabling researchers to convert cell-free DNA (cfDNA) liquid biopsy samples into libraries for next-generation sequencing (NGS) within eight hours. This innovation enhances the detection of somatic mutations in low-concentration cfDNA, vital for cancer diagnosis and monitoring.
The panels will be showcased at the AACR 2023 conference and can detect variants as low as 0.1% variant allele frequency. Additionally, QIAGEN will introduce new pan-cancer panels for its QIAcuity digital PCR platform in fall 2023, designed for efficient analysis of important cancer-related genes.
QIAGEN aims to improve cancer research and patient outcomes with these advancements, including precise mutation detection and streamlined workflows, enhancing laboratory productivity.
Summary not available.
Summary not available.
QIAGEN N.V. (NYSE: QGEN) has filed its annual report on Form 20-F for the year ending December 31, 2022, with the U.S. Securities and Exchange Commission. The report is available for access on QIAGEN’s website. The company provides free printed copies of the annual report to shareholders upon request. QIAGEN is a leading provider of Sample to Insight solutions, offering technologies for isolating and processing biomolecules. As of December 31, 2022, the company employed approximately 6,200 people globally, serving over 500,000 customers across various sectors such as molecular diagnostics and academia.
QIAGEN has partnered with Servier to develop a PCR test for detecting isocitrate dehydrogenase-1 (IDH1) mutations in acute myeloid leukemia (AML) patients. This companion diagnostic will be utilized with Servier’s TIBSOVO®, an IDH1 inhibitor treatment. The test will run on QIAGEN's Rotor-Gene Q device, targeting blood and bone marrow samples. QIAGEN, a leader in companion diagnostics, collaborates with over 30 companies to advance precision medicine. The collaboration aims to enhance patient access to targeted treatments for the 6-10% of AML patients with IDH1 mutations, showcasing QIAGEN's commitment to innovation in oncology diagnostics.
SOPHiA GENETICS (Nasdaq: SOPH) has entered into a partnership with QIAGEN (NYSE: QGEN) to integrate QIAseq reagent technology with its SOPHiA DDM™ platform. This collaboration aims to enhance tumor analysis through next-generation sequencing (NGS), specifically supporting somatic variant detection related to homologous recombination repair. The partnership allows customers to access QIAseq panels for improved data analysis, enhancing research capabilities in oncology. Both companies are optimistic about the positive impact on medicine and research.